利拉鲁肽对糖尿病肾病患者肾功能及CTRP3水平的影响  

Effect of liraglutide on renal function and CTRP 3 level in patients with diabetic nephropathy

作　　者：张亮[1] 卞帅博[1] 裴启秀 董金山 杨璇[1] ZHANG Liang;BIAN Shuaibo;PEI Qixiu;DONG Jinshan;YANG Xuan(Department of Nephrology,Jiangsu Province(Suqian)Hospital,Jiangsu Province,Suqian 223800,China)

机构地区：[1]江苏省人民医院宿迁医院肾内科,江苏省宿迁市223800

出　　处：《临床合理用药》2025年第7期41-44,共4页Chinese Journal of Clinical Rational Drug Use

基　　金：宿迁市市级指导性科技计划项目(Z2022089)。

摘　　要：目的观察利拉鲁肽对糖尿病肾病(DN)患者肾功能及C1q肿瘤坏死因子相关蛋白3(CTRP3)水平的影响。方法采用前瞻性、单中心、随机对照试验,纳入2020年1月—2023年12月在江苏省人民医院宿迁医院诊治的DN患者60例,采用随机数字表法分为试验组(n=30)和对照组(n=30)。对照组接受常规治疗,试验组在常规治疗的基础上接受利拉鲁肽治疗,2组治疗周期均为12周。比较2组治疗前后肾功能指标[血肌酐、24 h尿蛋白定量、估算肾小球滤过率(eGFR)]、血清CTRP3、糖化血红蛋白(HbA_(1c))、总胆固醇(TC)水平及血压。结果治疗12周后,试验组血肌酐、24 h尿蛋白定量、HbA_(1c)、TC水平及收缩压、舒张压低于治疗前(P<0.01),而对照组血肌酐、24 h尿蛋白定量、HbA_(1c)、TC水平及收缩压、舒张压与治疗前比较差异无统计学意义(P>0.05),且试验组血肌酐、24 h尿蛋白定量、HbA_(1c)、TC水平及收缩压、舒张压低于对照组(P<0.05或P<0.01);2组eGFR、血清CTRP3水平高于治疗前,且试验组高于对照组(P<0.05或P<0.01)。结论利拉鲁肽对DN患者的肾功能具有显著保护作用,可通过提高CTRP3水平发挥肾脏保护效应,且能够改善血糖、血脂代谢,有利于控制血压。Objective To observe the effect of liraglutide on renal function and CTRP3 level in patients with diabetic nephropathy(DN).Methods A prospective,single-center,randomized controlled trial was conducted on 60 DN patients admitted to Jiangsu Province(Suqian)Hospital from January 2020 to December 2023,and they were divided into experimental group(n=30)and control group(n=30)by using the random number table method.The control group received conventional treatment,and the experimental group received liraglutide treatment on the basis of conventional treatment,and the treatment cycle of the two groups was 12 weeks.Renal function indexes(blood creatinine,24 h urine protein quantification,eGFR),serum CTRP3,HbA_(1c),total cholesterol(TC)and blood pressure were compared between the two groups before and after treatment.Results After 12 weeks of treatment,blood creatinine,24 h urine protein quantification,HbA_(1c),TC levels and systolic and diastolic blood pressure in the test group were lower than before treatment(P<0.01),while blood creatinine,24 h urine protein quantification,HbA_(1c),TC levels and systolic and diastolic blood pressure were not statistically significant compared with those before treatment(P>0.05),and blood creatinine,24 h urine protein quantification,HbA_(1c),TC levels and systolic and diastolic blood pressure in the experimental group were lower than those in the control group(P<0.05 or P<0.01).The levels of eGFR and serum CTRP3 of the two groups were higher than before treatment,and the experimental group was higher than those in the control group(P<0.05 or P<0.01).Conclusion Liraglutide has a significant protective effect on the renal function of DN patients,which can play a renal protective effect by increasing the level of CTRP3,and it can improve the metabolism of blood glucose and lipid,which is conducive to the control of blood pressure.

关 键 词：糖尿病肾病 利拉鲁肽 肾功能 C1q肿瘤坏死因子相关蛋白3 

分 类 号：R54[医药卫生—心血管疾病]